Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2010 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Neurologix Completes Additional $7 Million Financing
    5. Neurologix Announces First Quarter 2011 Financial Results
    6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
    8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
    11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
    (Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
    (Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
    Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
    ... June 3, 2007 - Schering-Plough Corp. announced ... maintenance chemotherapy with,Caelyx (pegylated liposomal doxorubicin hydrochloride),significantly ... with,metastatic breast cancer with infrequent and manageable ... presented,today at the 43rd Annual Meeting of ...
    ... of Largest Ever Phase III Clinical Trial ... /PRNewswire-FirstCall/ --,GlaxoSmithKline today announced final results of ... investigational MAGE-A3,Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3,positive ... Cell Lung Cancer,(NSCLC). These data were presented ...
    Cached Medicine Technology:Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 2Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 3Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 4Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 6
    (Date:9/30/2014)... A new study of 58 ... impact of stress on metabolism after eating a high-fat meal ... a fast food restaurant, about 930 calories and 60 grams ... minutes every hour for 7 hours, conducting the study twice ... had experienced a stressful event in their lives during the ...
    (Date:9/30/2014)... granted new patient appointments to Medicaid beneficiaries and ... care practices (non-FQHCs), in addition to charging less ... 10-state University of Pennsylvania study published this month ... from a previous "secret shopper" study conducted in ... community health clinics that receive federal funding ...
    (Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
    (Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... certified nutrition specialist and best-selling author Mike Geary that is ... totally transform their body into a fat-burning machine in less ... prompting an investigative review. , “In our culture that ... can be hard to decipher what is really fact and ...
    (Date:9/30/2014)... VisitandCare.com reports that revenue for ... more than 79 percent in 2014, marking five straight ... total revenue tripled for its entirety of partnered medical ... has allowed them to partner with plastic surgery ... and privacy — with state-of-the-art surgical atmospheres aimed to ...
    Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
    ... cancer patients of reproductive age, radiation treatment directly to ... direct relationship between certain types of radiation therapy and ... 1 issue of the International Journal of Radiation ... for Radiation Oncology (ASTRO). , Radiation therapy to ...
    ... with schizoaffective disorder who received paliperidone extended release ... improvement in a broad range of schizoaffective symptoms, ... the 12th International Congress on Schizophrenia Research (ICOSR) ... study provide additional evidence for symptomatic improvement of ...
    ... Federally Employed Women (FEW) salutes the House ... included two very important federal worker provisions. An ... Stephen Lynch (D-9-MA) to include the Federal Employees ... legislation during a previous mark up of the ...
    ... researchers say it,s not clear if one causes the ... research provides more evidence of a link between sleeplessness ... whether insomnia actually makes people want to kill themselves. ... problems might be an important contributor to suicidal thinking," ...
    ... release is available in Spanish . ... study of working memory. In terms of information retention, ... affected in diseases such as Alzheimer, and short-term or ... or structure a discourse. This more ephemeral memory is ...
    ... of Children and Adults Living with Autism , ... ... non-profit provider of autism services, Easter Seals believes every ... to a continuum of appropriate autism resources and receive necessary services, ...
    Cached Medicine News:Health News:Some radiation therapy treatments can decrease fertility 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 7Health News:FEW Salutes House for Passing Legislation with Federal Worker Provisions; FERS Sick Leave Credit and FERS Redeposit Approved 2Health News:FEW Salutes House for Passing Legislation with Federal Worker Provisions; FERS Sick Leave Credit and FERS Redeposit Approved 3Health News:Insomnia Linked to Suicidal Thoughts, Attempts 2Health News:Insomnia Linked to Suicidal Thoughts, Attempts 3Health News:Activation of the prefrontal cortex improves working memory 2Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 2Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 3Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 4
    6 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm, 1 x 2. Orientation: Left hand....
    0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
    Stainless steel model of the popular Nordan titanium Colibri forceps. Tying platform with 0.12 mm teeth for grasping delicate structures. Flattened round handle with polished finish....
    0.12 mm, 1 x 2 teeth set at 45 degrees with 4.5 mm tying platform. Serrated handle with polished finish....
    Medicine Products: